Teva launches generic pulmonary hypertension drug

Teva Photo: Reuters Ammar Awad

Teva EVP: This launch is an important addition to our portfolio of generic medicines that treat complex conditions.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of ALYQ, a generic version of 20 mg. ADCIRCA (tadalafil) tablets in the US.

ALYQ is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. PAH is high blood pressure in the blood vessels of the lungs.

Teva EVP and Head of North America Commercial Brendan O’Grady said, “This launch is an important addition to our portfolio of generic medicines that treat complex conditions and we’re proud to offer an affordable treatment option for this rare disease.”

With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

ADCIRCA had annual sales of $490 million in the US, according to IQVIA data as of November 2018.

Published by Globes, Israel business news - en.globes.co.il - on February 6, 2019

© Copyright of Globes Publisher Itonut (1983) Ltd. 2019

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Teva Photo: Reuters Ammar Awad
Teva Photo: Reuters Ammar Awad
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018